{"nctId":"NCT00359983","briefTitle":"Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB","startDateStruct":{"date":"2006-09"},"conditions":["Neisseria Meningitidis","Haemophilus Influenzae Type b"],"count":270,"armGroups":[{"label":"MenHibrix 4-dose group","type":"EXPERIMENTAL","interventionNames":["Biological: MenHibrix (Hib-MenCY-TT)"]},{"label":"ActHIB 4-dose group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Hib conjugate vaccine (ActHIB)"]},{"label":"ActHIB 3-dose + MenHibrix 4th-dose group","type":"EXPERIMENTAL","interventionNames":["Biological: MenHibrix (Hib-MenCY-TT)","Biological: Hib conjugate vaccine (ActHIB)"]}],"interventions":[{"name":"MenHibrix (Hib-MenCY-TT)","otherNames":["GSK biologicals' Hib-MenCY-TT"]},{"name":"Hib conjugate vaccine (ActHIB)","otherNames":["ActHIB"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy male and female children who completed the previous four dose vaccination series study (NCT00129129). The age of the child at the 3 post-fourth dose timelines are as follows:\n\n  * Year 1: 22 to 36 months of age.\n  * Year 3: 44 to 60 months of age.\n  * Year 5: 5 years post-dose 4 +/- 8 weeks\n* Written informed consent obtained from the parent or guardian of the subject.\n* Healthy subjects as established by medical history and clinical examination before entering into the study\n* Having completed the fourth dose vaccination of study Hib-MenCY-TT-005/006\n\nExclusion Criteria:\n\nChildren should not have:\n\n* received more than 4 doses of Hib or meningococcal serogroup C and Y vaccine\n* had a history of H. influenzae type b, meningococcal serogroup C and Y diseases","healthyVolunteers":true,"sex":"ALL","minimumAge":"22 Months","maximumAge":"60 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Anti- Polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to 0.15 Microgram Per Milliliter","description":"Results up to 5 years after the fourth dose are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Neisseria Meningitidis Serogroup C (MenC) Antibody Titers Greater Than or Equal to 1:8 as Measured by Serum Bactericidal Assay Using Human Complement (hSBA)","description":"Results up to 5 years after the fourth dose are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Neisseria Meningitidis Serogroup Y (MenY) Antibody Titers Greater Than or Equal to 1:8 as Measured by Serum Bactericidal Assay Using Human Complement (hSBA)","description":"Results up to 5 years after the fourth dose are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Geometric Mean Concentrations (GMCs)","description":"Concentration were measured as Geometric Mean Concentrations expressed as microgram per milliliter (Âµg/mL).\n\nResults up to 5 years after the fourth dose are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.400","spread":null},{"groupId":"OG001","value":"1.943","spread":null},{"groupId":"OG002","value":"1.162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.169","spread":null},{"groupId":"OG001","value":"1.031","spread":null},{"groupId":"OG002","value":"0.898","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.248","spread":null},{"groupId":"OG001","value":"0.803","spread":null},{"groupId":"OG002","value":"0.689","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PRP Antibody Concentrations Greater Than or Equal to 1.0 Microgram Per Milliliter","description":"Results up to 5 years after the fourth dose are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"hSBA-MenC Geometric Mean Titers (GMTs)","description":"Titers are given as Geometric Mean Titers as measured by human serum bactericidal assay (hSBA) and expressed as the reciprocal of the dilution resulting in 50% inhibition.\n\nResults up to 5 years after the fourth dose are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150.1","spread":null},{"groupId":"OG001","value":"3.9","spread":null},{"groupId":"OG002","value":"26.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.9","spread":null},{"groupId":"OG001","value":"2.7","spread":null},{"groupId":"OG002","value":"16.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.8","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"44.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenC Titers Greater Than or Equal to 1:4","description":"Results up to 5 years after the fourth dose are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"hSBA-MenY Geometric Mean Titers (GMTs)","description":"Titers are given as Geometric Mean Titers as measured by human serum bactericidal assay (hSBA) and expressed as the reciprocal of the dilution resulting in 50% inhibition.\n\nResults up to 5 years after the fourth dose are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128.8","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"41.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":null},{"groupId":"OG001","value":"3.5","spread":null},{"groupId":"OG002","value":"16.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"17.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenY Titers Greater Than or Equal to 1:4","description":"Results up to 5 years after the fourth dose are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":138},"commonTop":[]}}}